Dutch Authority for Consumers and Markets will further clarify guideline “Collective procurement of prescription drugs” based on SiRM evaluation
In June 2016, the Dutch Authority for Consumers and Markets (ACM) published the guideline “Collective procurement of prescription drugs for medical specialist care (MSC)”. In this guideline, the ACM describes a so-called “safe harbor“ in which collective procurement is permitted. The ACM published this guideline to clarify the opportunities for collective procurement permitted within competition rules. The ACM expects that collective procurement could help procurement agents to negotiate lower prices for drugs and better conditions, which benefits patients and the insured.
The ACM decided in advance to evaluate the guideline after three years. The ACM has asked strategic consultant firm SiRM to carry out this evaluation and to investigate the effect of the guideline and possibilities for improvement or expansion of the guideline.
The ACM has announced to clarify the guideline based on the SiRM evaluation. The safe harbor could, for example, be expanded by describing the permitted options and topics for information sharing between parties in a procurement organization. In addition, it could be expanded by describing the permitted possibilities for stricter admission criteria for procurement organizations for the benefit of strengthening their implementation power. Furthermore the ACM will research how they can guide procurement agents of medical devices on how to procure collectively within competition rules.